Clearside’s CLS-AX shows promise in treatment of wet age-related macular degeneration
Patients with wet age-related macular degeneration receiving CLS-AX achieved stable visual acuity, and retinal thickness for up to six months. ...
Tag: macular degeneration
Stereotactic radiotherapy reduces anti-VEGF injection requirements in neovascular age-related macular degeneration
1. Fewer anti-VEGF intravitreal injections were required in the SRT group over 2 years. 2. Change in visual acuity was ...
#VisualAbstract: Low-Dose Daily Aspirin does not Affect the Progression of Age-Related Macular Degeneration
Click here to read this study in JAMA Ophthalmology. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
High dose aflibercept may be promising for treatment of age-related macular degeneration
1. Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events ...
Avacincaptad pegol reduces the rate of age-related macular degeneration in geographic atrophy
1. Avacincaptad pegol significantly slowed geographic atrophy over 12 months. 2. Exudative macular neovascularization was comparable among treatment groups. Evidence ...
Monthly brolucizumab is noninferior to aflibercept in treating recalcitrant wet age-related macular degeneration
1. In a phase 3a randomized trial comparing intravitreal brolucizumab to aflibercept for refractory neovascular age-related macular degeneration (nAMD), there ...
Faricimab noninferior to aflibercept for treatment of neovascular age-related macular degeneration
1. In both trials, faricimab was demonstrated to be non-inferior to aflibercept at improving visual acuity in neovascular age-related macular ...
Combination of corticosteroid and nonsteroidal anti-inflammatory drug eye drops non-superior to nonsteroidal anti-inflammatory drug monotherapy and sub-Tenon depot for postoperative macular thickening after cataract surgery
1. The findings demonstrated non-superiority of using a combination of prednisolone and nonsteroidal anti-inflammatory drug eye drops compared to nonsteroidal ...
Patient Basics: Macular Degeneration
Originally published by Harvard Health. What Is It? Macular degeneration is a common cause of blindness and vision problems among older ...
Key factors for non-response to ranibizumab in macular degeneration identified
Image: PD 1. Fibrovascular pigment epithelial detachment (PED) and serous PED were associated with non-response to intravitreal ranibizumab treatment as ...